{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose&page=24", "query": { "intervention": "Dose", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 50407, "total_pages": 5041, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T04:09:39.189Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07227649", "title": "NAC-REPAIR for Post-surgical Pain", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carpal Tunnel Surgery", "Trigger Finger Disorder", "De Quervain Syndrome", "Guyon's Canal", "Dupuytren Contracture", "Morton Neuroma", "Tarsal Tunnel Syndrome", "Plantar Fasciopathy", "Peroneal Nerve Entrapment" ], "interventions": [ { "name": "NAC", "type": "DRUG" }, { "name": "NAC 0mg/day (Placebo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 80, "start_date": "2026-10-15", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-27T04:09:39.189Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227649" }, { "nct_id": "NCT01382238", "title": "Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infections, Human Immunodeficiency Virus and Herpesviridae" ], "interventions": [ { "name": "Dolutegravir 50 mg tablet", "type": "DRUG" }, { "name": "Dolutegravir 50 mg oral granules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2011-06", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2011-09-19", "last_synced_at": "2026-10-27T04:09:39.189Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01382238" }, { "nct_id": "NCT02352558", "title": "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancy" ], "interventions": [ { "name": "BBI608", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2015-05", "completion_date": "2019-05-16", "has_results": false, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-10-27T04:09:39.189Z", "location_count": 8, "location_summary": "Denver, Colorado • Indianapolis, Indiana • Germantown, Tennessee + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02352558" }, { "nct_id": "NCT04887948", "title": "Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Disease", "COVID-19", "SARS-CoV-2 Infection" ], "interventions": [ { "name": "20-valent pneumococcal conjugate vaccine (20vPnC)", "type": "BIOLOGICAL" }, { "name": "BNT162b2", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 570, "start_date": "2021-05-20", "completion_date": "2021-12-08", "has_results": true, "last_update_posted_date": "2022-12-14", "last_synced_at": "2026-10-27T04:09:39.189Z", "location_count": 27, "location_summary": "Anaheim, California • Walnut Creek, California • Coral Gables, Florida + 21 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887948" }, { "nct_id": "NCT01007448", "title": "Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Refractory Cutaneous T-cell Lymphoma" ], "interventions": [ { "name": "Bexarotene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2010-01-06", "completion_date": "2014-02-20", "has_results": true, "last_update_posted_date": "2019-11-12", "last_synced_at": "2026-10-27T04:09:39.189Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01007448" }, { "nct_id": "NCT02274155", "title": "Anti-OX40 Antibody in Head and Neck Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Anti-OX40 antibody administration", "type": "DRUG" }, { "name": "Surgical Resection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2014-11-12", "completion_date": "2023-12-21", "has_results": false, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-10-27T04:09:39.189Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02274155" }, { "nct_id": "NCT01689155", "title": "Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Meningitis", "Meningococcal Infection" ], "interventions": [ { "name": "Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "9 Months", "maximum_age": "23 Months", "sex": "ALL", "summary": "9 Months to 23 Months" }, "enrollment_count": 116, "start_date": "2011-06", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2016-11-11", "last_synced_at": "2026-10-27T04:09:39.189Z", "location_count": 1, "location_summary": "Oakland, California", "locations": [ { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01689155" }, { "nct_id": "NCT06614855", "title": "A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma (GBM)", "Astrocytoma", "Astrocytoma, Grade III", "Astrocytoma, Grade IV", "Gliosarcoma, Adult", "Gliosarcoma of Brain" ], "interventions": [ { "name": "C134", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James Markert, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2025-06-02", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-27T04:09:39.189Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06614855" }, { "nct_id": "NCT04975555", "title": "Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cytokine Release Syndrome", "ICANS", "Lymphoma, Non-Hodgkin", "Multiple Myeloma", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Siltuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-11-15", "completion_date": "2026-01-20", "has_results": true, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-27T04:09:39.189Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975555" }, { "nct_id": "NCT00287326", "title": "Comparison of Low-dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Bupivacaine, Clonidine, Morphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "4 Years to 16 Years" }, "enrollment_count": 40, "start_date": "2006-01", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2016-04-19", "last_synced_at": "2026-10-27T04:09:39.189Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00287326" } ] }